Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

The primary purpose of this study is to identify an appropriate dose of study medication.


January 31, 2014
Rheumatology - Rheumatoid Arthritis
Philip J. Mease, MD

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association (ARA) [1987] or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) [2010]) at least 16 weeks prior to screening
  • ACR global functional status class of 1 to 3
  • Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors
  • ...
Reda Tipton
206-386-3806
206-386-3201